RU2696584C1 - Композиции и способы, используемые для лечения симптомов нижних мочевых путей, доброкачественной гиперплазии предстательной железы, эректильной дисфункции и других заболеваний или симптомов - Google Patents

Композиции и способы, используемые для лечения симптомов нижних мочевых путей, доброкачественной гиперплазии предстательной железы, эректильной дисфункции и других заболеваний или симптомов Download PDF

Info

Publication number
RU2696584C1
RU2696584C1 RU2016122062A RU2016122062A RU2696584C1 RU 2696584 C1 RU2696584 C1 RU 2696584C1 RU 2016122062 A RU2016122062 A RU 2016122062A RU 2016122062 A RU2016122062 A RU 2016122062A RU 2696584 C1 RU2696584 C1 RU 2696584C1
Authority
RU
Russia
Prior art keywords
dosage form
subject
acid
symptoms
form according
Prior art date
Application number
RU2016122062A
Other languages
English (en)
Russian (ru)
Other versions
RU2016122062A (ru
Inventor
Эмили Анни Клоди ФРОМЕНТЭН
Дуглас Эндрю КЛЕЙБЕР
Дэниел Дэвид СОУЗА
Original Assignee
НАТЮРЕКС-ДиБиЭс ЭлЭлСи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53042226&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2696584(C1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by НАТЮРЕКС-ДиБиЭс ЭлЭлСи filed Critical НАТЮРЕКС-ДиБиЭс ЭлЭлСи
Publication of RU2016122062A publication Critical patent/RU2016122062A/ru
Application granted granted Critical
Publication of RU2696584C1 publication Critical patent/RU2696584C1/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/45—Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RU2016122062A 2013-11-11 2014-11-11 Композиции и способы, используемые для лечения симптомов нижних мочевых путей, доброкачественной гиперплазии предстательной железы, эректильной дисфункции и других заболеваний или симптомов RU2696584C1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361902376P 2013-11-11 2013-11-11
US61/902,376 2013-11-11
PCT/US2014/064961 WO2015070203A1 (en) 2013-11-11 2014-11-11 Compositions and methods useful in treatment of lower urinary tract sysptoms, benign prostatic hyperplasia, erectile dysfunction

Publications (2)

Publication Number Publication Date
RU2016122062A RU2016122062A (ru) 2017-12-19
RU2696584C1 true RU2696584C1 (ru) 2019-08-05

Family

ID=53042226

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2016122062A RU2696584C1 (ru) 2013-11-11 2014-11-11 Композиции и способы, используемые для лечения симптомов нижних мочевых путей, доброкачественной гиперплазии предстательной железы, эректильной дисфункции и других заболеваний или симптомов

Country Status (21)

Country Link
US (5) US20160324911A1 (cg-RX-API-DMAC7.html)
EP (2) EP3782634B1 (cg-RX-API-DMAC7.html)
JP (2) JP6966196B2 (cg-RX-API-DMAC7.html)
KR (2) KR102476969B1 (cg-RX-API-DMAC7.html)
CN (2) CN105848663A (cg-RX-API-DMAC7.html)
AU (1) AU2014346415B2 (cg-RX-API-DMAC7.html)
BR (1) BR112016010509B1 (cg-RX-API-DMAC7.html)
CA (2) CA3277615A1 (cg-RX-API-DMAC7.html)
CL (1) CL2016001109A1 (cg-RX-API-DMAC7.html)
CR (1) CR20160254A (cg-RX-API-DMAC7.html)
ES (2) ES2980381T3 (cg-RX-API-DMAC7.html)
IL (1) IL245552B (cg-RX-API-DMAC7.html)
MX (1) MX373448B (cg-RX-API-DMAC7.html)
MY (1) MY184225A (cg-RX-API-DMAC7.html)
NZ (1) NZ719268A (cg-RX-API-DMAC7.html)
PH (1) PH12016500780A1 (cg-RX-API-DMAC7.html)
PL (1) PL3068414T3 (cg-RX-API-DMAC7.html)
RU (1) RU2696584C1 (cg-RX-API-DMAC7.html)
SG (2) SG11201603462SA (cg-RX-API-DMAC7.html)
WO (1) WO2015070203A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201602941B (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2840322C2 (ru) * 2022-12-19 2025-05-21 Александр Владимирович Синица Композиция с использованием метаболитов Bacillus subtilis для лечения заболеваний мочевыводящих путей

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2696584C1 (ru) * 2013-11-11 2019-08-05 НАТЮРЕКС-ДиБиЭс ЭлЭлСи Композиции и способы, используемые для лечения симптомов нижних мочевых путей, доброкачественной гиперплазии предстательной железы, эректильной дисфункции и других заболеваний или симптомов
JP6412291B1 (ja) * 2017-01-20 2018-10-24 マルカイコーポレーション株式会社 頻尿の改善剤
CN107647387A (zh) * 2017-08-15 2018-02-02 孟广千 用于补膀胱的保健食品
IT201800007473A1 (it) 2018-07-24 2020-01-24 Sistema di aggancio ad evidenza di manomissione, procedimento per la realizzazione di detto sistema di aggancio, contenitore comprendente detto sistema di aggancio ed uso di quest'ultimo
JP7219907B2 (ja) * 2018-07-25 2023-02-09 株式会社 沖縄リサーチセンター 下部尿路症状改善用組成物
JP6738388B2 (ja) * 2018-09-27 2020-08-12 マルカイコーポレーション株式会社 頻尿の改善剤
US20200360466A1 (en) * 2019-05-13 2020-11-19 Nymox Corporation Method of improving lower urinary tract symptoms
CA3160517A1 (en) * 2019-11-08 2021-05-14 Cj Cheiljedang Corporation A composition for use in reducing an off-taste or off-flavor comprising chlorogenic acid, caffeic acid, and quinic acid
WO2022045846A1 (ko) * 2020-08-31 2022-03-03 건국대학교 글로컬산학협력단 미선나무 추출물을 유효성분으로 포함하는 안드로겐 수용체 관련 질환 치료용 약학적 조성물
WO2022189010A1 (en) * 2021-03-07 2022-09-15 Givaudan Sa Methods and compositions for treating and preventing urinary tract infections
KR102388984B1 (ko) * 2021-11-16 2022-04-20 재단법인 전남바이오산업진흥원 모새나무 열매 추출물을 유효성분으로 포함하는 전립선 비대증 예방 또는 치료용 약학조성물
WO2025038998A1 (en) * 2023-08-17 2025-02-20 University Of Wyoming Materials and methods for inhibiting, preventing, and dispersing biofilms
CN121985956A (zh) 2023-10-09 2026-05-05 奇华顿股份有限公司 组合物
CN120204245A (zh) * 2024-12-12 2025-06-27 湖北医药学院 连翘苷在制备预防或治疗高尿酸血症的药物中的应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5525341A (en) * 1992-10-09 1996-06-11 Jlb, Inc. Partially purified cranberry anti-adhesion activity
US20010012525A1 (en) * 1998-04-30 2001-08-09 Mann Douglas L. Infused vegetable, herb, and/or seed fiber product and dietary supplements containing same
US20050186147A1 (en) * 2004-02-04 2005-08-25 Foamix Ltd. Cosmetic and pharmaceutical foam with solid matter
US20110280971A1 (en) * 2000-05-12 2011-11-17 Timothy Heeg Berry oils and products
US20130122151A1 (en) * 2011-11-16 2013-05-16 Decas Botanical Synergies, Llc Process for Spray Drying Botanical Food

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US20010025059A1 (en) 2000-01-10 2001-09-27 Kastke Floyd A. Composition and method for treating non-bacterial prostatitis
US6391345B1 (en) 2000-05-12 2002-05-21 Tim Heeg Cranberry seed oil, cranberry seed flour and a method for making
JP2001342142A (ja) * 2000-06-01 2001-12-11 Nissui Pharm Co Ltd 泌尿器系疾患予防治療用組成物
US7270837B2 (en) * 2003-11-10 2007-09-18 Rutgers, The State University Of New Jersey Anti-inflammatory cranberry flavonol extract preparations
US8153166B2 (en) * 2006-06-08 2012-04-10 Chih-Hsiung Lin Composition for prophylaxis or treatment of urinary system infection and method thereof
EP2170352A1 (en) * 2007-06-27 2010-04-07 Coloplast A/S Treatment of urinary tract infections with a mixture of saponin and an antibiotic
CN101095764B (zh) * 2007-07-13 2010-05-19 天津天狮生物发展有限公司 具有辅助治疗女性泌尿道感染的保健食品
US8173178B1 (en) 2007-08-03 2012-05-08 Decas Botanical Synergies, Llc Compositions and methods for controlling metabolic syndrome using whole fruit-derived cranberry ingredient profile enriched in stress adapted bioactives (SABs)
US20090175843A1 (en) * 2008-01-08 2009-07-09 Medical Nutrition Usa, Inc. Composition for prevention or treatment of urinary tract infection
US20110064706A1 (en) 2008-01-11 2011-03-17 U.S. Nutraceuticals, Llc D/B/A Valensa International Method of preventing, controlling and ameliorating urinary tract infections and supporting digestive health by using a synergistic cranberry derivative, a d-mannose composition and a proprietary probiotic blend
US20090180999A1 (en) * 2008-01-11 2009-07-16 U.S. Nutraceuticals, Llc D/B/A Valensa International Method of preventing, controlling and ameliorating urinary tract infections using cranberry derivative and d-mannose composition
EP2156835A1 (en) * 2008-08-19 2010-02-24 Sanofi-Aventis New therapeutic use of drotaverine
WO2011088420A1 (en) 2010-01-15 2011-07-21 Ocean Spray Cranberries, Inc. Process for extracting compound from cranberry leaves and related products
CN101999648B (zh) * 2010-10-11 2012-10-31 宝鸡市虹源生物科技有限公司 蔓越橘果实中花色苷及原花青素类成分的提取方法
JP2012171899A (ja) * 2011-02-21 2012-09-10 Unitika Ltd 尿路感染症予防改善剤
FR2972328A1 (fr) * 2011-03-07 2012-09-14 Walmark A S Complement alimentaire augmentant la protection de l'epithelium des voies urinaires basses contre les infections a repetition
RU2696584C1 (ru) * 2013-11-11 2019-08-05 НАТЮРЕКС-ДиБиЭс ЭлЭлСи Композиции и способы, используемые для лечения симптомов нижних мочевых путей, доброкачественной гиперплазии предстательной железы, эректильной дисфункции и других заболеваний или симптомов

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5525341A (en) * 1992-10-09 1996-06-11 Jlb, Inc. Partially purified cranberry anti-adhesion activity
US20010012525A1 (en) * 1998-04-30 2001-08-09 Mann Douglas L. Infused vegetable, herb, and/or seed fiber product and dietary supplements containing same
US20110280971A1 (en) * 2000-05-12 2011-11-17 Timothy Heeg Berry oils and products
US20050186147A1 (en) * 2004-02-04 2005-08-25 Foamix Ltd. Cosmetic and pharmaceutical foam with solid matter
US20130122151A1 (en) * 2011-11-16 2013-05-16 Decas Botanical Synergies, Llc Process for Spray Drying Botanical Food

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
П.К.КЬОСЕВ. Полный справочник лекарственных растений, Эксмо-Пресс, Москва, 2001, стр.693-694. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2840322C2 (ru) * 2022-12-19 2025-05-21 Александр Владимирович Синица Композиция с использованием метаболитов Bacillus subtilis для лечения заболеваний мочевыводящих путей

Also Published As

Publication number Publication date
EP3068414A1 (en) 2016-09-21
ES2860773T3 (es) 2021-10-05
CL2016001109A1 (es) 2016-12-02
IL245552A0 (en) 2016-06-30
AU2014346415A1 (en) 2016-05-12
SG10201910781SA (en) 2020-01-30
MX2016005810A (es) 2016-11-18
US12233101B2 (en) 2025-02-25
US20190358282A1 (en) 2019-11-28
CN105848663A (zh) 2016-08-10
JP2020059725A (ja) 2020-04-16
CN116077548A (zh) 2023-05-09
US11291703B2 (en) 2022-04-05
JP2016539183A (ja) 2016-12-15
KR102476969B1 (ko) 2022-12-12
ZA201602941B (en) 2022-05-25
KR20230004886A (ko) 2023-01-06
JP6966196B2 (ja) 2021-11-10
US20180256663A1 (en) 2018-09-13
PH12016500780B1 (en) 2016-06-13
EP3068414A4 (en) 2017-06-07
US10898534B2 (en) 2021-01-26
ES2980381T3 (es) 2024-10-01
US20220175863A1 (en) 2022-06-09
US20200121750A1 (en) 2020-04-23
EP3068414B1 (en) 2020-12-30
KR102745710B1 (ko) 2024-12-20
BR112016010509B1 (pt) 2021-08-17
AU2014346415B2 (en) 2020-04-23
WO2015070203A9 (en) 2016-01-14
US11045511B2 (en) 2021-06-29
PH12016500780A1 (en) 2016-06-13
CA2928631A1 (en) 2015-05-14
CA2928631C (en) 2025-08-12
PL3068414T3 (pl) 2021-08-30
WO2015070203A1 (en) 2015-05-14
MY184225A (en) 2021-03-28
NZ719268A (en) 2021-07-30
RU2016122062A (ru) 2017-12-19
US20160324911A1 (en) 2016-11-10
MX373448B (es) 2020-06-11
BR112016010509A2 (pt) 2017-08-08
EP3782634B1 (en) 2024-03-20
KR20160079884A (ko) 2016-07-06
CA3277615A1 (en) 2025-10-30
SG11201603462SA (en) 2016-05-30
JP7083330B2 (ja) 2022-06-10
IL245552B (en) 2020-07-30
CR20160254A (es) 2016-08-31
EP3782634A1 (en) 2021-02-24

Similar Documents

Publication Publication Date Title
US12233101B2 (en) Compositions and methods useful in treatment of lower urinary tract symptoms, benign prostatic hyperplasia, erectile dysfunction, and other diseases or symptoms
Singh et al. Health benefits of resveratrol: Evidence from clinical studies
Saltan et al. Viburnum opulus L.: A remedy for the treatment of endometriosis demonstrated by rat model of surgically-induced endometriosis
JP7473516B2 (ja) 腸の健康を促す組成物
Ma et al. Effect of pomegranate peel polyphenols on human prostate cancer PC-3 cells in vivo
TW201016228A (en) Extracts of cranberry and methods of using thereof
WO2016036882A1 (en) Green tea compositions
Cao et al. Alleviation of glucolipotoxicity-incurred cardiomyocyte dysfunction by Z-ligustilide involves in the suppression of oxidative insult, inflammation and fibrosis
AU2018278312A1 (en) Methods and compositions for treating congenital diarrhea disorder
US20220080021A1 (en) Composition for preventing or treating prostatic hyperplasia comprising mixed extracts of curcumae radix and syzygii flos
HK1228782B (en) Compositions and methods useful in treatment of lower urinary tract sysptoms, benign prostatic hyperplasia, erectile dysfunction
HK1228782A1 (en) Compositions and methods useful in treatment of lower urinary tract sysptoms, benign prostatic hyperplasia, erectile dysfunction
Angelopoulos et al. Α Randomized, Placebo-Controlled Trial to assess the Efficacy and Safety of a Novel Nutraceutical Combination of Monacolin K and Bergamot extract in subjects with Mild to Moderate Hypercholesterolemia
BAYRAKTAR et al. The Health Effects of Polyphenols and Mental Health